相关实验视频
Updated: Jun 24, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
结合性败血症和功能障碍诱导的低血糖症在老年患者服用齐本林
Tatsuki Iha1,2, Ayako Watanabe1,2, Misa Saeki1,2
1Department of Pharmacy Showa University Koto Toyosu Hospital Tokyo Japan.
Clinical case reports
|June 4, 2024
概括
患有败血症的老年患者可能会经历低血糖 (低血糖) 由于cibenzoline,即使药物水平正常. 在向患有严重感染的老年患者施用西宾林时,仔细监测血糖至关重要.
科学领域:
- 老年医学 老年医学
- 临床药理学 临床药理学
- 心脏病学 心脏病学
背景情况:
- 败血症在老年患者中提出了独特的挑战.
- 西宾林用于心脏病,但可能有副作用.
- 药物诱导的低血糖在老年人中是一个严重的问题.
研究的目的:
- 在患有败血症的老年患者中报告西宾林诱导的低血糖病例.
- 突出注意药物监测和老年患者剂量调整的重要性.
- 为了强调需要警血糖在治疗期间的血糖波动.
主要方法:
- 一个86岁的男性患者因败血症入院的病例报告.
- 监测血液中的齐本林水平和血糖.
- 停止治疗并随后重新服用降低剂量的齐本林.
- 通过静脉注射葡萄糖治疗低血糖的管理.
主要成果:
- 患者在重新开始服用50毫克/天的西宾林后出现低血糖症 (64毫克/分升),尽管血液中的治疗水平.
- 低血糖发生了尽管患者的败血症和功能障碍.
- 这一案例说明了这种人群中基本和低血糖之间的潜在联系.
结论:
- 临床医生必须在给患有严重感染的老年患者开药时保持谨慎.
- 在这些患者中,应密切监测血糖水平,无论血度如何.
- 需要进一步的研究,以阐明在老年人群中引发的低血糖症的机制和患病率.
相关概念视频
Hypoglycemia and Glucagon
256
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
256
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
Factors Affecting Renal Clearance: Renal Impairment
84
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
84
Renal Failure: Dose Adjustments
84
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
84
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173

